Remove Immune Response Remove Licensing Remove Production
article thumbnail

GreenLight and US NIH partner to develop Covid-19 vaccine for variants

Pharmaceutical Technology

They intend to develop vaccines that provide lasting immune responses compared to existing vaccines. The human health product candidates of GreenLight are currently in the pre-clinical stage. Furthermore, the parties will collaborate on the joint development of systems that accelerate the latest designs into clinical usage.

Vaccine 245
article thumbnail

Meningitis vaccine comes to the forefront with impressive study results

Pharmaceutical Technology

The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. The response was more powerful than that generated by MenACWY-D – a licensed quadrivalent meningococcal vaccine marketed by GSK.

Vaccine 195
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biologic Therapeutics Development, Part 2: Regulatory Pathways and Pharmacometric Analysis

Camargo

The development of biological products (or biologics) represents a major advancement in modern medicine, enabling the treatment of patients with many illnesses where no other therapeutics were previously available. The regulations regarding BLAs for therapeutic biological products are included in 21 CFR parts 600 , 601 , and 610.

article thumbnail

Evaxion and ExpreS²ion partner to develop new CMV vaccine

Pharmaceutical Technology

According to the agreement, ExpreS 2 ion will hold the exclusive right for licensing the CMV vaccine candidate under a possible development and commercialisation agreement. Until 2025, the companies will equally share the research and intellectual property licensing expenses under the partnership.

Vaccine 130
article thumbnail

South Korea authorises Novavax Covid-19 vaccine as booster dose

Pharmaceutical Technology

The findings showed that the Nuvaxovid booster dose increased immune responses compared to higher levels associated with the protection in Phase III clinical trials. Nuvaxovid demonstrated a significant antibody response when given as a booster dose after primary vaccination with other authorised Covid-19 doses in the COV-BOOST trial.

Vaccine 147
article thumbnail

AbbVie preps filings for lymphoma bispecific licensed from Genmab

pharmaphorum

Epcoritamab is a bispecific antibody which targets CD3 on white blood cells and CD20 on tumour cells, and is designed to encourage an immune response against the cancer. billion product at peak. The post AbbVie preps filings for lymphoma bispecific licensed from Genmab appeared first on.

article thumbnail

BioNTech Partners with Matinas BioPharma to Develop New Delivery Technology for mRNA Vaccines

XTalks

In a joint news release , Matinas and BioNTech said they’ve also started discussions on a license agreement for Matinas’ LNC platform. Related: BioNTech Unveils the BioNTainer, a Modular mRNA Vaccine Factory to Help Production in Africa. “We

Vaccine 105